In 559 adults with early type 2 diabetes on diet and exercise alone, once-daily oral orforglipron (3, 12 or 36 mg) cut HbA1c more than placebo at 40 weeks (difference −0.83 to −1.07 points); GI events were common, with more adverse-event discontinuation than placebo.
RCTn = 559
Rosenstock et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes